NCT00367991View on ClinicalTrials.gov

Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Myocardial Infarction
Interventions
DRUG

Recombinant human erythropoietin alfa (drug)

200 U/kg IV daily for 3 days vs. matched volume of normal saline IV daily for 3 days

DRUG

Placebo

Normal saline to match active drug (rHuEpo)

Trial Locations (1)

06510

Yale University, New Haven

All Listed Sponsors
collaborator

American Heart Association

OTHER

lead

Yale University

OTHER

NCT00367991 - Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction | Biotech Hunter | Biotech Hunter